Drug Launch Strategy: What Pharma Marketers Get Wrong

A drug launch strategy is the commercial and marketing plan that takes a new pharmaceutical product from regulatory approval to market adoption. It covers positioning, channel selection, audience segmentation, pricing, and the sequencing of activities that drive prescriber uptake and patient access. Done well, it is one of the most complex go-to-market executions in any industry. Done poorly, it is one of the most expensive failures you will ever witness.

The stakes are not abstract. A misread launch window, a positioning decision that underestimates clinical inertia, or a channel mix that talks to the wrong prescriber tier can cost tens of millions before anyone realises the strategy is off. I have worked across more than 30 industries, and pharmaceutical launches sit in a category of their own for the gap between strategic ambition and commercial execution.

Why Most Drug Launches Underperform in Year One

The pharmaceutical industry has a well-documented problem with launch performance. A significant proportion of new drugs fail to hit their year-one revenue targets, and the gap between projected and actual uptake is rarely explained by the science. The product often works exactly as the clinical data suggested. The failure is commercial.

I spent time working with a healthcare communications team on a specialty launch, and the pattern was familiar from other industries: the commercial team had been handed a positioning brief written by medical affairs, the sales force had been trained on mechanism of action rather than prescriber objections, and the launch budget had been allocated based on historical spend norms rather than channel effectiveness data. Nobody had asked the fundamental question: what does a prescriber actually need to believe before they write the first script?

That question sounds simple. It is not. It requires understanding clinical inertia, which is the tendency for prescribers to stay with established treatment protocols until the evidence for change becomes overwhelming or a trusted peer endorses the switch. It requires understanding payer dynamics, because a drug that is not on formulary is a drug that does not get prescribed regardless of how good the sales rep’s pitch is. And it requires understanding patient pathways, because in many therapeutic areas the prescriber is not the first point of contact.

For teams thinking about the broader mechanics of commercial planning, the articles in the Go-To-Market and Growth Strategy hub cover a range of frameworks that apply across sectors, including pharma. The principles of sequencing, segmentation, and channel prioritisation are not industry-specific, even if the regulatory context is.

The Positioning Problem in Pharmaceutical Marketing

Positioning a new drug is harder than positioning most products because the claims you can make are constrained by regulatory approval, and the audience you are talking to is trained to be sceptical of promotional messaging. Physicians have seen hundreds of product launches. They know the pattern. They know that every new molecule is presented as a meaningful advance. Many are not.

The positioning challenge is to find the specific clinical context where your drug genuinely performs better than the standard of care, and to communicate that with enough specificity that a prescriber can immediately map it to a patient type they see regularly. Broad efficacy claims do not move prescribers. Narrow, credible, patient-specific claims do.

This is where I see pharma marketing teams make a mistake that I have seen in other B2B categories too. They write positioning for the average prescriber rather than for the early adopter. The early adopter in any market, including clinical medicine, is not looking for the same reassurance as the mainstream. They are looking for differentiation, for clinical interest, for a reason to engage with something new. If your launch positioning is written to satisfy the sceptic, you will not convert the early adopter, and without early adopters you do not build the peer influence that moves the mainstream.

The segmentation logic here is similar to what I have seen work in B2B financial services marketing, where the decision-making unit is complex, the buyers are sophisticated, and the messaging has to be calibrated differently for different stages of the adoption curve. The mechanics are different, but the underlying commercial logic is the same.

Prescriber Segmentation: The Commercial Hypothesis You Have to Test

Most pharmaceutical companies segment prescribers by decile, which is a volume-based ranking derived from prescription data. The top decile writes the most scripts, so they get the most sales force attention. It is a logical starting point and a deeply insufficient strategy.

Volume-based segmentation tells you who is active in a therapeutic area. It does not tell you who is likely to adopt a new product, who has the peer influence to accelerate uptake in their network, or who is treating the specific patient population your drug is best suited for. A high-volume prescriber who is deeply committed to an existing treatment protocol is a harder conversion than a mid-volume prescriber who has been frustrated by the limitations of current options.

Effective segmentation for a drug launch should combine prescription volume with attitudinal data, patient mix analysis, and network influence mapping. That last one is underused. In clinical medicine, adoption spreads through professional networks. A key opinion leader who endorses your drug at a regional conference can move more prescriptions than a hundred sales calls. Identifying those nodes in the prescriber network, and building a strategy to engage them early, is one of the highest-leverage activities in a launch plan.

If you are building or auditing the digital infrastructure to support that kind of segmentation and targeting, a structured analysis of your digital assets is worth doing before you commit budget. In pharma, the HCP portal, the medical affairs content, and the patient support resources all need to work as a coherent system, not as isolated channels.

Channel Strategy: Where Pharma Marketing Wastes the Most Money

I have managed hundreds of millions in ad spend across a range of industries, and the pattern of misallocation in pharmaceutical marketing is consistent. Too much money goes into broad awareness channels that are easy to measure by impression metrics and too little goes into the high-intent, high-specificity channels where prescribing decisions are actually influenced.

Endemic advertising is one of those underused channels. In the pharmaceutical context, endemic advertising means placing content within the clinical media that prescribers already read: medical journals, specialty news platforms, clinical decision support tools, and continuing medical education environments. These are not mass channels. They are precision channels. The audience is small, the intent is high, and the context is directly relevant to the prescribing decision you are trying to influence.

The reason endemic advertising gets under-resourced is partly structural. Media agencies are incentivised by volume, and a targeted buy in a specialty clinical platform does not generate the impression numbers that look impressive in a quarterly review. But if you are launching a drug for a rare disease or a narrow indication, impressions from a general health audience are commercially irrelevant. The metric that matters is reach within the prescriber population, and endemic channels deliver that more efficiently than almost anything else.

Digital channels for HCP engagement have also matured significantly. Programmatic targeting using verified HCP data, email programmes through medical society partnerships, and video content distributed through clinical platforms all offer measurable engagement with prescriber audiences. The increasing complexity of go-to-market execution in regulated industries makes channel discipline more important, not less. Spreading budget thinly across every available channel is a way of being everywhere and effective nowhere.

For the patient-facing side of a launch, the channel logic is different but the discipline is the same. Direct-to-consumer advertising is heavily regulated in most markets outside the United States. Where it is permitted, the creative and media strategy needs to be built around patient activation, which means driving awareness of a condition and encouraging conversations with physicians, rather than making product claims that will be scrutinised by regulators and sceptical prescribers alike.

The Payer Strategy That Most Launch Teams Underestimate

In markets with significant third-party payer coverage, whether that is private insurance in the United States or national health systems in Europe, the payer conversation is not a downstream activity. It is a precondition for commercial success. A drug that is not covered, or that sits on a formulary tier that requires prior authorisation, will not reach patients regardless of how effective the prescriber marketing is.

Payer strategy needs to begin during clinical development, not after approval. The data that payers need to make coverage decisions, health economic modelling, comparative effectiveness evidence, real-world data on patient outcomes, is not always the same data that the FDA or EMA requires for approval. Companies that treat payer evidence as a post-approval problem often find themselves in extended coverage negotiations that delay commercial uptake by 12 to 18 months.

The messaging architecture for payers is also fundamentally different from the messaging for prescribers. Payers are not evaluating clinical elegance. They are evaluating cost-effectiveness, budget impact, and the size of the patient population likely to use the drug. A launch team that runs the same core messaging across both audiences is making a category error that compounds over time as the payer relationship becomes more adversarial and the prescriber messaging gets diluted by economic language it was not designed to carry.

This is an area where the rigour of digital marketing due diligence has a direct parallel in pharmaceutical market access planning. Before committing to a launch strategy, you need an honest audit of where your evidence base is strong, where it has gaps, and what those gaps will cost you in payer negotiations. Optimism about coverage timelines is one of the most expensive assumptions a launch team can make.

Sales Force Deployment and the Field Execution Gap

The pharmaceutical sales force is still the primary channel for HCP engagement in most therapeutic areas, even as digital channels have grown. But the way most companies deploy their field teams at launch reflects organisational inertia more than commercial strategy.

The default approach is to hire a large field force, assign territories based on geography, and train everyone on the same product messages. The problem is that launch dynamics are not geographically uniform. Adoption tends to cluster around academic medical centres, key opinion leaders, and specific practice types before it spreads to the broader prescriber population. A geographically distributed field force deployed at launch is often the wrong shape for the actual commercial opportunity.

Early in my career, I had a moment that stuck with me. I was handed responsibility I had not expected, in a room where the structure had just dissolved and the work still needed to happen. The lesson I took from it was that the shape of your team at the start of a project rarely matches the shape of the problem. You have to be willing to redeploy quickly. In pharmaceutical launches, that means building field deployment models that can flex as adoption data comes in, rather than locking in a coverage model six months before launch and hoping the market behaves as planned.

There is also a growing role for non-personal promotion in complementing field activity. Medical science liaisons, digital medical education, and appointment-based engagement models that prioritise quality of interaction over volume of calls are all gaining traction in markets where prescriber access is tightening. The days of measuring field force effectiveness purely by call frequency are over in most sophisticated markets.

Pre-Launch Preparation: The 18-Month Window That Determines Everything

The decisions that determine launch success are almost always made before the approval date. The 18 months prior to launch are when the commercial strategy gets set, the positioning gets tested, the payer evidence gets assembled, and the field force gets trained. By the time the approval comes through, you are executing a plan, not building one.

Companies that treat approval as the starting gun for commercial preparation are already behind. I have seen this pattern in other industries too: the tendency to treat the product release date as the moment when marketing begins, rather than the moment when a long preparation period pays off. At lastminute.com, we could turn a paid search campaign live and see revenue within hours. Pharmaceutical launches do not have that luxury. The lead times are longer, the stakeholder map is more complex, and the cost of a slow start compounds over the product lifecycle.

Pre-launch preparation should include disease awareness campaigns that build the market before the product is available, key opinion leader engagement programmes that begin 12 to 18 months before approval, payer dossier development that runs in parallel with regulatory submission, and market research that tests positioning hypotheses with real prescribers rather than relying on internal assumptions.

The commercial transformation frameworks from BCG are worth reviewing in this context. The principle that go-to-market strategy needs to be built around how customers actually make decisions, rather than how companies prefer to sell, is directly applicable to pharmaceutical launches where the prescribing decision involves multiple stakeholders, multiple information sources, and a clinical risk calculus that marketing alone cannot override.

Measuring Launch Performance Without Misleading Yourself

Launch metrics in pharma tend to cluster around prescription volume, market share, and share of voice. These are useful indicators, but they are trailing measures. By the time they show a problem, the commercial window for correction has often narrowed significantly.

Leading indicators matter more in the early months of a launch. Prescriber trial rates, repeat prescription rates, patient persistence on therapy, and payer coverage status are all signals that tell you whether the commercial engine is working before the volume numbers confirm or deny it. A drug with good trial rates but poor persistence has a different problem than a drug with low trial rates. The intervention required is different. Treating them as the same problem because the prescription volume looks similar is a diagnostic failure.

I have judged the Effie Awards, where effectiveness is the entire point of the evaluation. The discipline that separates strong entries from weak ones is not the quality of the creative or the scale of the media spend. It is the clarity of the commercial objective and the honesty of the measurement framework. The same discipline applies in pharmaceutical launches. If your measurement framework is designed to make the launch look successful rather than to accurately diagnose commercial performance, you will make decisions based on a false picture and the market will eventually correct you.

For teams building out the organisational structure to manage this kind of launch complexity, the corporate and business unit marketing framework offers a useful lens on how to allocate responsibility between centralised strategy and local execution. In global pharmaceutical launches, that tension between global brand consistency and local market adaptation is one of the most persistent sources of commercial underperformance.

The pricing and go-to-market dynamics that BCG has documented in complex B2B markets also have direct relevance here. Pharmaceutical pricing is its own discipline, but the underlying logic of how price signals interact with market positioning and channel strategy applies across categories.

If you are working through the broader commercial planning questions that sit behind a launch, the Go-To-Market and Growth Strategy hub covers the frameworks and principles that apply across industries, including the ones that pharma teams tend to rediscover the hard way. The fundamentals of market segmentation, positioning, channel selection, and launch sequencing do not change because the product is regulated.

What a Strong Drug Launch Strategy Actually Looks Like

A strong drug launch strategy is not a comprehensive plan that covers every possible scenario. It is a focused commercial hypothesis about where adoption will begin, how it will spread, and what needs to be true for the product to reach its commercial potential. Everything else is execution detail.

That hypothesis needs to be specific enough to be tested. It needs to name the prescriber segments where early adoption is most likely, the clinical context where the product genuinely outperforms the standard of care, the payer environment that will determine patient access, and the channels that will most efficiently reach each audience. Vague strategies that describe the market rather than a plan for winning in it are not strategies. They are descriptions dressed up as plans.

The companies that execute strong launches tend to have a few things in common. They start commercial preparation earlier than their competitors. They test positioning with real prescribers before committing to it. They build payer evidence in parallel with regulatory evidence rather than sequentially. They deploy field resources in the shape of the early adoption opportunity rather than in the shape of the eventual market. And they measure leading indicators honestly rather than waiting for volume data to confirm what the early signals already told them.

None of this is complicated in principle. The execution is hard because it requires cross-functional alignment across medical, commercial, regulatory, and market access teams that often have different priorities and different definitions of success. The marketing function in a pharmaceutical launch is not just a communications operation. It is a commercial coordination function, and the leaders who understand that tend to run better launches than the ones who treat it as a messaging problem.

For a broader perspective on the growth mechanics that sit behind any market entry strategy, the tools and frameworks used in growth strategy offer useful context, even if the pharmaceutical application requires significant adaptation for the regulatory environment. And for teams thinking about how audience and channel dynamics interact at launch, the principles of creator-led go-to-market have an interesting parallel in the key opinion leader programmes that drive early clinical adoption.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions